A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195

B. J. Eigl; S. North; E. Winquist; D. Finch; L. Wood; S. S. Sridhar; J. Powers; J. Good; M. Sharma; J. A. Squire; J. Bazov; T. Jamaspishvili; M. E. Cox; P. A. Bradbury; E. A. Eisenhauer; K. N. Chi

doi:10.1007/s10637-015-0252-4

A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195

B. J. Eigl, S. North, E. Winquist, D. Finch, L. Wood, S. S. Sridhar, J. Powers, J. Good, M. Sharma, J. A. Squire, J. Bazov, T. Jamaspishvili, M. E. Cox, P. A. Bradbury, E. A. Eisenhauer, K. N. Chi

科研成果: 期刊稿件 › 文章 › 同行评审

52 引用（Scopus）

源语言	英语
页（从-至）	969-976
页数	8
期刊	Investigational New Drugs
卷	33
期	4
DOI	https://doi.org/10.1007/s10637-015-0252-4
出版状态	已出版 - 8月 2015
已对外发布	是

!!!ASJC Scopus Subject Areas

药学（医学）
肿瘤学
药理学

联合国可持续发展目标

此成果有助于实现下列可持续发展目标：

访问文件

10.1007/s10637-015-0252-4

其它文件与链接

引用此

Eigl, B. J., North, S., Winquist, E., Finch, D., Wood, L., Sridhar, S. S., Powers, J., Good, J., Sharma, M., Squire, J. A., Bazov, J., Jamaspishvili, T., Cox, M. E., Bradbury, P. A., Eisenhauer, E. A., & Chi, K. N. (2015). A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195. Investigational New Drugs, 33(4), 969-976. https://doi.org/10.1007/s10637-015-0252-4

Eigl, BJ, North, S, Winquist, E, Finch, D, Wood, L, Sridhar, SS, Powers, J, Good, J, Sharma, M, Squire, JA, Bazov, J, Jamaspishvili, T, Cox, ME, Bradbury, PA, Eisenhauer, EA & Chi, KN 2015, 'A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195', Investigational New Drugs, 卷 33, 号码 4, 页码 969-976. https://doi.org/10.1007/s10637-015-0252-4

@article{1e5a001010b34a2b992b3c53b0564757,

title = "A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195",

keywords = "Castration resistant prostate cancer, HDAC, Histone deacetylase inhibitors",

author = "Eigl, {B. J.} and S. North and E. Winquist and D. Finch and L. Wood and Sridhar, {S. S.} and J. Powers and J. Good and M. Sharma and Squire, {J. A.} and J. Bazov and T. Jamaspishvili and Cox, {M. E.} and Bradbury, {P. A.} and Eisenhauer, {E. A.} and Chi, {K. N.}",

note = "Publisher Copyright: {\textcopyright} Springer Science+Business Media New York 2015.",

year = "2015",

month = aug,

doi = "10.1007/s10637-015-0252-4",

language = "English",

volume = "33",

pages = "969--976",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "Kluwer Academic Publishers",

number = "4",

}

TY - JOUR

T1 - A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer

T2 - NCIC clinical trials group study IND195

AU - Eigl, B. J.

AU - North, S.

AU - Winquist, E.

AU - Finch, D.

AU - Wood, L.

AU - Sridhar, S. S.

AU - Powers, J.

AU - Good, J.

AU - Sharma, M.

AU - Squire, J. A.

AU - Bazov, J.

AU - Jamaspishvili, T.

AU - Cox, M. E.

AU - Bradbury, P. A.

AU - Eisenhauer, E. A.

AU - Chi, K. N.

PY - 2015/8

Y1 - 2015/8

KW - Castration resistant prostate cancer

KW - HDAC

KW - Histone deacetylase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84944441620&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944441620&partnerID=8YFLogxK

U2 - 10.1007/s10637-015-0252-4

DO - 10.1007/s10637-015-0252-4

M3 - Article

C2 - 25983041

AN - SCOPUS:84944441620

SN - 0167-6997

VL - 33

SP - 969

EP - 976

JO - Investigational New Drugs

JF - Investigational New Drugs

IS - 4

ER -

A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195

!!!ASJC Scopus Subject Areas

联合国可持续发展目标

访问文件

其它文件与链接

指纹

引用此